Cuba Offers Innovative Treatment for Diabetic Foot Ulcer
Summary: Cuba’s Center for Genetic Engineering and Biotechnology offers Heberprot-P, a recombinant human EGF for DFUs, achieving 75% healing and 70% amputation reduction vs 30% standard. Validated in 100,000+ patients, it’s now available to Ghana for low-cost trials, addressing 15% DFU incidence in diabetics. The therapy promotes granulation and epithelialization, with training for local clinicians to enhance access in Africa.
Key Highlights:
- Heberprot-P: EGF stimulates cell proliferation; 75% healing in trials.
- Impact: 70% fewer amputations; used in 20+ countries.
- Ghana Offer: Low-cost supply; training for MDT implementation.
- Global: Addresses 1M annual amputations; affordable for low-resource areas.
- Quote: Trivedi: “Innovative solution for DFU crisis in Africa.”
Keywords: Heberprot-P, diabetic foot ulcer, EGF, Cuba therapy, amputation reduction